Alzheimer's disease drug development pipeline: 2025
University of Nevada, Las Vegas · Cleveland Clinic Lerner College of Medicine · +2 more institutions
Abstract
Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease-targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the…
Citation impact
- FWCI
- 110.50
- Percentile
- 100%
- References
- 16
Authors
7Topics & keywords
- Disease
- Drug development
- Pipeline (software)
- Drug
- Medicine
- Neuroscience
- Intensive care medicine
- Psychology
Funding
- AAAlzheimer's AssociationAwards: ALZDISCOVERY-1051936, ALZDISCOVERY‐1051936
- ADAlzheimer's Drug Discovery FoundationAward: P20GM109025
- NINational Institute on AgingAwards: R25AG083721, P20GM109025, U01AG073323, R01AG082118, R56AG074001, RF1AG082211, R01AG076448, R21AG083003, R25AG083721-01, R01AG066707, R35AG71476, R01AG084250
- NINational Institute of General Medical SciencesAwards: P20GM109025, NIA R35AG71476
- NINational Institute of Neurological Disorders and StrokeAward: RO1NS139383